All In Biotech

Drug Trial Radar · NCT07872423

Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Tiral of Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection (VDJ001) in the Treatment of Idiopathic Multicentric Castleman Disease (iMCD)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jan 27, 2025

Primary completion

Jun 9, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Beijing VDJBio Co., LTD.Industry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).

Conditions

  • Anti IL-6R
  • Castleman's Disease, Multicentric

Interventions

  • Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody InjectionDrug

    VDJ001 is a recombinant humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R). It is produced using Chinese hamster ovary (CHO) cells through DNA recombinant technology. The antibody specifically binds to both soluble and membrane-bound IL-6R (sIL-6R and mIL-6R), thereby inhibiting signal transduction mediated by sIL-6R or mIL-6R.

  • PlaceboDrug

    This is a matching placebo formulation containing no active pharmaceutical ingredient (API). The placebo is manufactured to be identical in appearance, color, shape, size, taste, and packaging to the investigational product VDJ001 to maintain the integrity of the double-blind design. It is utilized solely as a control intervention for the purpose of this randomized, double-blind, placebo-controlled clinical trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving a comprehensive response, defined as complete response (CR) or partial response (PR), sustained for at least 18 weeks, based on combined assessment of symptoms, biochemical efficacy, and overall lymph node evaluation.Time frame: 30/36 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Xiamen Branch,Zhongshan hospital,Fudan University

    Xiamen, Fujian, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Suncy0618@163.Com

    Chengdu, Sichuan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.